Enlivex Cuts 60% of Workforce, Winds Down Non-Clinical R&D to Fund Phase 2b Trial
ENLV is trading near its 52-week low of $0.205 (5.6% above the low).
Summary
Enlivex announced an immediate cost reduction plan — about 60% workforce cut, non-clinical R&D wound down, management pay cut 20% and CEO pay 40% — to conserve cash and fund its Phase 2b Allocetra knee OA trial, with topline six-month data expected by mid-2027.
Key Events · Legal and Risk Events · ENLV
-
Cost Reduction Plan Launched
Effective immediately, Enlivex is winding down all non-clinical R&D and concentrating resources on the Phase 2b Allocetra trial in age-related knee osteoarthritis.
-
60% Workforce Cut
Headcount is being reduced by approximately 60%, with management salaries cut 20% and the CEO's salary cut 40%.
-
Cash Burn and Financing Risk
The plan is designed to substantially reduce cash burn, but the filing states the company may still be unable to obtain additional financing on acceptable terms, or at all, to fund the Phase 2b trial through topline data.
-
Phase 2b Data Targeted Mid-2027
Topline six-month endpoint data from the randomized, placebo-controlled Phase 2b trial is expected by mid-2027; the FDA granted RMAT designation for this population in July 2026.
Analysis · ENLV · Crypto Assets
Enlivex is shrinking to a single bet: the Phase 2b Allocetra knee osteoarthritis trial, with six-month topline data expected by mid-2027. Cutting roughly 60% of staff, winding down all non-clinical R&D, and reducing management pay 20% (CEO 40%) buys runway, but it also means the company is conserving cash rather than expanding — and the filing itself flags the risk that it may still be unable to raise the additional financing needed to fund the trial through topline data. For a company this small, the plan is a survival move that pushes the entire thesis onto one readout roughly nine months out.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENLV was trading at $0.22 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.20 to $27.15. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.